Iagaru Andrei, Wang Yingbing, Mari Carina, Quon Andrew, Goris Michael L, Horning Sandra, Gambhir Sanjiv Sam
Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Dr, Room H-0101, Stanford, CA 94305-5427, USA.
Hell J Nucl Med. 2008 Sep-Dec;11(3):153-6.
Assessing the response to treatment as soon after treatment initiation is one of the key reasons for imaging lymphoma patients. The optimal time after initiating treatment for assessing response to treatment has yet to be determined. Therefore, we were prompted to review our experience with serial (18)F-FDG PET/CT in patients undergoing treatment for Hodgkin's disease (HD) and non Hodgkin's lymphoma (NHL). This is a retrospective study (Feb 2003 - Oct 2004) of 20 patients, 11 men and 9 women, with age range of 7-75 years with diagnosis of HD (10) and NHL (10), who had PET/CT at our institution prior, during and at the completion of therapy. Restaging PET/CT was done after 2 cycles of chemotherapy in 10 patients (group A) and after 4 cycles of chemotherapy in 10 pts (group B). A total of 60 scans were reviewed. The DeltaSUV from baseline to first PET/CT was on average 67.6% in group A and 75.1% in group B. This had no statistical significance (P value: 0.31). The DeltaSUV from baseline to post-therapy PET/CT was on average 72.9% in group A and 79.8% in group B. This difference also had no statistical significance (P value: 0.24). The correlation coefficient was 0.98 in group A and 0.80 in group B. Results of PET/CT after 2 cycles of chemotherapy did not statistically differ from the results of PET/CT after 4 cycles of chemotherapy. These results need to be confirmed in larger, prospective, randomized trials.
在治疗开始后不久评估治疗反应是对淋巴瘤患者进行成像检查的关键原因之一。开始治疗后评估治疗反应的最佳时间尚未确定。因此，我们促使回顾我们在接受霍奇金病（HD）和非霍奇金淋巴瘤（NHL）治疗的患者中进行系列（18）F-FDG PET/CT检查的经验。这是一项回顾性研究（2003年2月至2004年10月），研究对象为20例患者，11例男性和9例女性，年龄范围为7至75岁，诊断为HD（10例）和NHL（10例），他们在我们机构治疗前、治疗期间和治疗完成时接受了PET/CT检查。10例患者（A组）在化疗2个周期后进行了再分期PET/CT检查，10例患者（B组）在化疗4个周期后进行了检查。共回顾了60次扫描。从基线到首次PET/CT的DeltaSUV在A组平均为67.6%，在B组平均为75.1%。这没有统计学意义（P值：0.31）。从基线到治疗后PET/CT的DeltaSUV在A组平均为72.9%，在B组平均为79.8%。这种差异也没有统计学意义（P值：0.24）。A组的相关系数为0.98，B组为0.80。化疗2个周期后的PET/CT结果与化疗4个周期后的PET/CT结果在统计学上没有差异。这些结果需要在更大规模的前瞻性随机试验中得到证实。
